![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines firm dedicated to delivering life-changing therapies for individuals battling devastating illnesses, introduced it’ll maintain an analyst and investor webcast on Wednesday, September 28, 2022. The occasion will spotlight WVE-006, Wave’s A-to-I RNA base enhancing oligonucleotide (“AIMer”) candidate for the remedy of alpha-1 antitrypsin deficiency (AATD), present views from an skilled in AATD, and define future therapeutic purposes of Wave’s best-in-class RNA enhancing functionality.
“Towards the Clinic: Spotlight on RNA Editing for AATD”
- Date: Wednesday, September 28, 2022
- Time: 10:00 a.m. – 11:30 a.m. EDT
The occasion will function shows from the Wave Life Sciences administration workforce together with Paul Bolno, MD, MBA, President and Chief Executive Officer, Paloma Giangrande, PhD, VP, Platform Discovery Sciences, Biology, and Chandra Vargeese, PhD, Chief Technology Officer and Head of Platform Discovery Sciences.
Dr. D. Kyle Hogarth, Professor of Medicine within the Section of Pulmonary and Critical Care Medicine on the University of Chicago, may even current. Dr. Hogarth is a well known medical skilled within the remedy of individuals dwelling with AATD. He serves because the Director of the Alpha-1 Clinical Resource Center on the University of Chicago and was co-author of the 2016 medical observe tips for AATD.
A Q&A session will observe the shows.
A hyperlink to register for the upcoming occasion is on the market right here. A reside webcast of the occasion will probably be accessible on the investor relations web page of the Wave Life Sciences company web site at http://ir.wavelifesciences.com. Following the reside occasion, an archived model of the webcast will probably be accessible on the Wave Life Sciences web site.
About WVE-006
WVE-006 is a PN-modified GalNAc-conjugated investigational growth candidate for the remedy of alpha-1 antitrypsin deficiency (AATD), designed to right the mutant SERPINA1 Z allele transcript to handle each liver and lung manifestations of illness. WVE-006 is a first-in-class RNA enhancing candidate (AIMer) and probably the most superior program at the moment in growth utilizing an oligonucleotide to harness an endogenous enzyme for enhancing.
About AIMers
Adenosine deaminases appearing on RNA (ADAR) enzymes are naturally occurring enzymes in people which catalyze adenine (A) to inosine (I) modifications in repetitive parts, microRNAs (miRNAs), and protein encoding transcripts. Wave’s A-to-I RNA base enhancing oligonucleotides (“AIMers”) are designed to recruit these endogenous ADAR enzymes to direct environment friendly and extremely particular enhancing of RNA transcripts. Because I is learn as G (guanine) by the mobile translational equipment, sequence-directed enhancing with ADAR has the potential to revert transcripts with single G-to-A degree mutations that trigger genetic illnesses.
About Alpha-1 antitrypsin deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) is an inherited genetic dysfunction that’s generally attributable to a G-to-A degree mutation (“Z allele”) within the SERPINA1 gene, which leads to lung illness due to lack of wild-type alpha1-antitrypsin (M-AAT) in lungs and liver illness due to aggregation of misfolded Z-AAT protein in hepatocytes.
About PRISM™
PRISM is Wave Life Sciences’ proprietary discovery and drug growth platform that allows genetically outlined illnesses to be focused with stereopure oligonucleotides throughout a number of therapeutic modalities, together with silencing, splicing, and enhancing. PRISM combines the corporate’s distinctive capability to assemble stereopure oligonucleotides with a deep understanding of how the interaction amongst oligonucleotide sequence, chemistry and spine stereochemistry impacts key pharmacological properties. By exploring these interactions by iterative evaluation of in vitro and in vivo outcomes and machine learning-driven predictive modeling, the corporate continues to outline design ideas which might be deployed throughout applications to quickly develop and manufacture medical candidates that meet pre-defined product profiles.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines firm dedicated to delivering life-changing therapies for individuals battling devastating illnesses. Wave aspires to develop best-in-class medicines throughout a number of therapeutic modalities utilizing PRISM, the corporate’s proprietary discovery and drug growth platform that allows the exact design, optimization, and manufacturing of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave workforce is concentrating on a broad vary of genetically outlined illnesses in order that sufferers and households could understand a brighter future. To discover out extra, please go to www.wavelifesciences.com and observe Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
[email protected]
Media Contact:
Alicia Suter
617-949-4817
[email protected]
